替比夫定与拉米夫定治疗慢性乙型肝炎临床效果对比分析  

Comparative analysis of clinical effect by telbivudine and lamivudine in the treatment of chronic hepatitis B

作　　者：王敏 WANG Min.(Liaoning Dalian City Sixth People＇s Hospital, Dalian 116031, China)

机构地区：[1]辽宁省大连市第六人民医院,116031

出　　处：《中国实用医药》2017年第7期116-118,共3页China Practical Medicine

摘　　要：目的分析替比夫定与拉米夫定治疗慢性乙型肝炎临床效果差异。方法 98例慢性乙型肝炎患者,随机分为甲组和乙组,各49例。甲组患者采用替比夫定治疗,乙组患者应用拉米夫定进行治疗。对两组疗效及安全性进行观察对比。结果甲组患者治疗总有效率为95.92%,乙组患者为77.55%,甲组患者的临床疗效高于乙组,差异具有统计学意义(P<0.05)。甲组患者病毒反跳发生率为2.04%,乙组为16.33%,甲组病毒反跳发生率明显低于乙组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率对比差异无统计学意义(P>0.05)。结论替比夫定治疗慢性乙型肝炎的疗效较拉米夫定更好,可减少反跳的发生,且不良反应少,具有较好的疗效与安全性,具有临床应用价值。Objective To analyze difference in clinical effect by telbivudine and lamivudine in the treatment of chronic hepatitis B. Methods A total of 98 patients with chronic hepatitis B were randomly divided into group A and group B, with 49 cases in each group. Group A received telbivudine for treatment, and group B received lamivudine for treatment. Comparison and observation were made on curative effect and safety between the two groups. Results Group A had total effective rate in treatment as 95.92%, which was 77.55% in group B. Group A had higher clinical effect than group B, and their difference had statistical significance（P〈0.05）. Group A had incidence of viral rebound as 2.04%, which was 16.33% in group B. Group A had much lower incidence of viral rebound than group B, and their difference had statistical significance（P〈0.05）. There was no statistical significance of incidence of adverse reactions between the two groups（P〉0.05）. Conclusion Telbivudine shows better curative effect than lamivudine in treating chronic hepatitis B, along with less viral rebound and adverse reactions. This method provides excellent curative effect and safety, and it contains clinical application value.

关 键 词：替比夫定 拉米夫定 慢性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]